New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
NCT ID NCT07692750
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests a new drug called IBI343, given together with standard chemotherapy pills (capecitabine) and sometimes another chemo drug (oxaliplatin), in people whose advanced pancreatic cancer has stopped responding to initial treatment. The goal is to find a safe dose and see whether the combination can shrink tumors. The trial enrolls adults with a specific marker on their cancer cells (CLDN18.2) and uses a step-by-step approach to check safety before expanding to more participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI343 (a targeted antibody) plus capecitabine with or without oxaliplatin
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced pancreatic cancer whose disease has progressed after initial chemotherapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. Side effects from the drug combination could be significant, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
- Drug cocktail aims to stall pancreatic cancer in patients who have run out of options
- Experimental combo targets Hard-to-Treat pancreatic cancer
- Engineered immune cells take aim at a common pancreatic cancer mutation
- Experimental vaccine combo takes on tough pancreatic cancer